Bright Minds Biosciences (DRUG) Total Liabilities (2020 - 2026)

Bright Minds Biosciences has reported Total Liabilities for 7 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 451.76% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 451.76% YoY), and the FY2025 full-year result was $1.7 million, up 314.57% from the prior year.
• Total Liabilities for Q1 2026 stood at $2.8 million, up from $1.1 million in the prior quarter.
• The five-year high for Total Liabilities was $2.8 million in Q1 2026, with the low at $130602.2 in Q2 2024.
• Historically, Total Liabilities has averaged $770744.7 across 5 years, with a median of $547032.6 in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities slumped 82.31% — and 2026, when it soared 451.76%.
• Bright Minds Biosciences' Total Liabilities stood at $429247.3 in 2022, then soared by 46.17% to $627410.9 in 2023, then tumbled by 34.78% to $409172.2 in 2024, then soared by 180.28% to $1.1 million in 2025, then surged by 143.7% to $2.8 million in 2026.
• The last three Total Liabilities figures came in at $2.8 million (Q1 2026), $1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.